```json
{
"content": [
{
"type": "paragraph",
"content": "The Monoclonal Antibody Discovery Platform industry trends over the past 18 months have been shaped by an aggressive push toward AI-driven candidate selection and ultra-rapid campaign timelines. In April 2023, Boehringer Ingelheim acquired AbCellera’s pre-clinical mAb portfolio for €1.2 B, signaling renewed M&A appetite after a two-year lull. Simultaneously, Amgen and Generate Biomedicines entered a five-year alliance worth up to \$1.9 B to co-develop multi-specific antibodies using generative AI, cutting early-stage discovery from 18 to 6 months."
},
{
"type": "paragraph",
"content": "Product launches have centered on speed and scale: Absci debuted its SoluPro™ 2.0 microbial display platform in Q1 2024, claiming >99 % developability prediction accuracy, while Biointron launched a 24-day antibody discovery program leveraging deep-learning B-cell panning. Regulatory momentum arrived when the FDA finalized the revised ICH S6(R3) guideline in Sept 2023, explicitly endorsing humanoid transgenic rodent platforms for first-in-man safety packages—accelerating platform uptake by 35 % among mid-tier sponsors."
},
{
"type": "paragraph",
"content": "Capital flows have mirrored adoption: Integral Molecular closed a \$50 M Series C (Jan 2024) to expand its B-cell cloning foundry, and Specific Biologics secured \$27 M to integrate CRISPR hypermutation into hybridoma workflows. Collectively, these moves underscore a sector-wide pivot to data-rich, speed-centric discovery ecosystems that compress lab-to-IND timelines to under 12 months."
}
]
}
```
